Apeiron scientists were authors/co-authors on three presentations at ASCO 2014 (May 30-June 3, 2014; Chicago)

The prestigious ASCO Annual Meeting is the largest clinical oncology conference worldwide. Two contributions informed about key results with the neuroblastoma antibody APN311. One presentation introduced the novel “checkpoint blockade” cancer immunotherapy approach APN401.